SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant discussion and price action driven by a political statement concerning institutional home buying. Despite an initial market reaction, the community largely views this as a bullish catalyst for Opendoor, asserting that as an iBuyer facilitating individual homeownership, the company benefits from reduced institutional competition and a revitalized consumer housing market. Many are interpreting the stock's volatility as an opportunity to accumulate shares, anticipating a strong upward move.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to a substantial price and volume surge, with community conversations heavily focused on a potential short squeeze driven by a high cost to borrow. Traders are actively anticipating a "supernova" run, drawing comparisons to its past volatile rallies and aiming for significant price levels. This intense action is dominating market discussion for the low-float stock.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is capturing significant attention following news of its innovative 3D-printed fuel tank preparing for an upcoming SpaceX mission, highlighting its role in space-based infrastructure. The community is actively discussing the company's remarkably low float and high short interest, sparking intense speculation about a potential short squeeze and drawing comparisons to early-stage space giants.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is gaining significant attention as it formally greenlit the construction of an Arctic-grade pilot plant and storage facility for its Tanbreez rare earth project in Greenland. This catalyst is intensified by active community discussion and political rhetoric regarding potential U.S. strategic interest or acquisition of Greenland for critical minerals, which many believe could lead to a substantial short squeeze and propel the stock higher due to its importance in diversifying rare earth supply chains.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending driven by its CES 2026 announcements regarding new AI PC processors built on its advanced 18A manufacturing process, alongside Mobileye's acquisition of Mentee Robotics. The community is divided, debating if these developments validate Intel's strategic turnaround in US chip production and AI, or if historical volatility and market skepticism will continue to challenge sustained gains.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is actively discussed following a Scotiabank downgrade to "Underperform," which the community largely views as a manipulative "hit piece" to benefit shorts or competitors. Investors are dismissing valuation concerns, buying dips, and holding strong, anticipating upcoming catalysts like the Bluebird 7 launch and MNO partnerships to continue the stock's significant upward momentum as a leader in global satellite-to-cellular connectivity.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing significant bullish momentum, driven by discussions around an increasingly constrained short float, high borrow fees, and calls for a massive short squeeze. The trading community is actively speculating on its potential for a parabolic upward move, drawing comparisons to its history of extreme volatility and other low-float "China pump" stocks.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics (GLUE) is gaining significant attention following positive interim Phase 1 data for its MRT-8102 molecular glue degrader, which demonstrated profound reductions in inflammatory markers for cardiovascular risk. This clinical advancement, alongside the company's substantial partnership with Novartis and notable short interest, is driving community discussions about the innovative platform's broad therapeutic potential and potential for further appreciation. Investors are actively debating the long-term value proposition and the possibility of a short squeeze.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is surging amidst immediate market chatter regarding proposed policy changes to restrict institutional single-family home purchases, alongside widespread community anticipation of a significant refinancing boom in 2026 as interest rates fall. Investors are actively discussing RKT's comprehensive mortgage and real estate ecosystem, enhanced by recent strategic acquisitions and AI investments, as a prime beneficiary of these evolving market conditions and favorable technical setups.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending due to circulating discussions about potential policy changes that could restrict institutional investors from purchasing single-family homes, sparking investor concern given its significant real estate holdings. The community is sharply divided, with many anticipating a negative impact on the alternative asset manager, while others view the resulting sell-off as an overreaction, noting the limited portion of single-family rentals within its vast portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD

Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ:MNKD - Free Report) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD

Calamos Advisors LLC acquired a new stake in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD

180 Wealth Advisors LLC lifted its position in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) by 11.2% during the third quarter, according to the company in its most recent filing with...

MannKind (NASDAQ:MNKD) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

MannKind (NASDAQ:MNKD) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened...

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key PointsCEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share...

<ul class="summary-bullets"><li>The FDA expanded Furoscix use to certain pediatric patients.</li><li>MannKind received five new U.S. patents supporting its ReadyFlow autoinjector, which is still under FDA review.</li><li>The FDA is expected to decide on the ReadyFlow application by July 26, 2026.</li></ul>MannKind Corp (MNKD) shares fell on Tuesday even as the company announced regulatory and patent updates tied to its&nbsp;Furoscix drug, which is used to treat fluid buildup in people with heart failure and kidney disease.At the time of writing, the stock fell 1.4% to $5.91.<h2 class="st-heading-2">Furoscix Gets Pediatric Approval</h2>The company said the U.S. Food and Drug Administration (FDA) approved wider use of&nbsp;Furoscix to include certain pediatric patients who weigh at least 43 kilograms. The drug was previously approved only for adults with fluid buildup caused by chronic heart failure or chronic kidney disease.The company’s chief medical officer said the approval makes&nbsp;Furoscix available to a limited pediatric group and provides an option for treatment outside the hospital for patients who meet the weight requirement.<h2 class="st-heading-2">Patents Support ReadyFlow Autoinjector</h2>MannKind also said it received five new U.S. patents related to its ReadyFlow autoinjector, a device under FDA review that is designed to deliver furosemide in seconds rather than hours.The patents cover the drug formulation and methods of treatment and could provide protection through 2040 if the product is approved. The company said the patents would be listed in the FDA’s Orange Book upon approval.ReadyFlow is based on technology developed by scPharmaceuticals, which MannKind acquired in August. Before the acquisition, scPharmaceuticals reported positive study results showing that the autoinjector delivered furosemide at levels comparable to intravenous dosing. In that study, patients had similar fluid removal results to IV treatment, reported little to no injection pain, and experienced side effects consistent with standard furosemide use.The company reiterated that the FDA is reviewing its application for ReadyFlow for use in adults with heart failure or kidney disease, with a decision expected by July 26, 2026.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MannKind was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnkd_ss_png_2d06a45896.webp" alt="mnkd ss.png" width="970" height="141"><figcaption>MNKD sentiment and message volume as of December 23| Source: Stocktwits</figcaption></figure>One user said the pediatric approval carries limited commercial impact but signals regulatory comfort with&nbsp;Furoscix, which could be supportive ahead of the FDA’s July 2026 decision on the ReadyFlow autoinjector.<stembedurl>https://stocktwits.com/kevinmik/message/639971814</stembedurl>Another retail investor questioned the timing of the announcement, noting it was released just ahead of the Christmas holiday when market activity is typically thin.<stembedurl>https://stocktwits.com/ChillyMutt/message/639959660</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 0.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind’s stock has declined 0.9% so far in 2025. (Photo credit: Getty Images)

MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?

Shares fell as investors flagged limited commercial impact from the pediatric approval and questioned the timing of the announcement during thin holiday trading.

Equity

Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

Insider Selling: MannKind (NASDAQ:MNKD) CEO Sells 20,806 Shares of Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 20,806 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $6.00...

MannKind (NASDAQ:MNKD) CEO Sells $124,836.00 in Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 20,806 shares of the business's stock in a transaction dated Friday, December 12th. The shares were sold at an average...

MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 21,310 Shares

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 21,310 shares of MannKind stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of...

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MNKD News

MNKDMannkind Corp